Additionally, increased tumor vessel permeability and drug delivery via the paracellular pathway have been achieved by intraperitoneal injection of a transforming growth factor β (TGF-β) inhibitor, which induces defects in pericyte coverage 141, or by using doxorubicin-containing MMP2-responsive nanoparticles that release an anti-platelet antibody, leading to local depletion of tumor-associated platelets adhering to the vessel wall 142. Here, TGFB1 is linked to neoplasm.